Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-P43 (ustekinumab biosimilar) AI vs PFS in healthy males
NCT06951828Phase 1Completed
- Sponsor
- Celltrion
- Start
- May 2025
- Primary completion
- Nov 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ustekinumab CT-P43 in plaque psoriasis, psoriatic arthritis (PsA), Crohn's disease and 1 more (2 arms), sponsored by Celltrion. Primary endpoints: Area under the concentration-time curve from time zero to infinity at Day 113 and Maximum serum concentration at Day 113. Started May 2025; status: completed.
02
Drugs
ustekinumab CT-P43
03
Conditions
plaque psoriasispsoriatic arthritis (PsA)Crohn's diseaseulcerative colitis (UC)
Beyond the preview
Go deeper on NCT06951828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06951828.